Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects
Vaccination toward SARS-CoV-2 reduced mortality and ‘boosters’ are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home “San Giuseppe Moscati” who had re...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2060018 |
| _version_ | 1797673196105760768 |
|---|---|
| author | Fabio Borgonovo Carlo Alberto Stangalini Carmine Tinelli Chiara Mariani Davide Mileto Maria Vittoria Cossu Laura Abbati Lara Bilardo Gloria Gagliardi Miriam Cutrera Martina Pellicciotta Luciana Armiento Gianfranco Dedivitiis Amedeo F. Capetti Giuliano Rizzardini |
| author_facet | Fabio Borgonovo Carlo Alberto Stangalini Carmine Tinelli Chiara Mariani Davide Mileto Maria Vittoria Cossu Laura Abbati Lara Bilardo Gloria Gagliardi Miriam Cutrera Martina Pellicciotta Luciana Armiento Gianfranco Dedivitiis Amedeo F. Capetti Giuliano Rizzardini |
| author_sort | Fabio Borgonovo |
| collection | DOAJ |
| description | Vaccination toward SARS-CoV-2 reduced mortality and ‘boosters’ are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home “San Giuseppe Moscati” who had received two doses of the BNT162b2 vaccine were enrolled. The antibody response was assessed by the DiaSorin LIAISON-CLIA S1/S2® IgG solution. Cutoff levels for response (>39 BAU/mL) and neutralizing activity (>208 BAU/mL) were derived from DiaSorin official data. Serology was assessed before and after the first vaccination, and 2 weeks and 6 months after the second vaccination. Anti-S IgG in COVID-19 experienced, baseline IgG producers spiked after the first vaccination to median 5044 BAU/mL and decayed at 6 months to 2467.4 BAU/mL. Anti-S IgG in COVID-19 experienced, baseline IgG non-producers spiked after the second vaccination to median 1701.7 BAU/mL and decayed at 6 months to 904.8 BAU/mL. Anti-S IgG in COVID-19 naïve subjects spiked after the second vaccination to median 546 BAU/mL and decayed at 6 months to 319.8 BAU/mL. The differences between sequential timepoint levels in each group were statistically significant (p < .0001). Serology analysis revealed different kinetics between COVID-19 experienced subjects depending on baseline response, possibly predicting different IgG persistence in blood. |
| first_indexed | 2024-03-11T21:41:38Z |
| format | Article |
| id | doaj.art-5934b4c6d3aa40d09f2d3daf13f8fda8 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:38Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-5934b4c6d3aa40d09f2d3daf13f8fda82023-09-26T13:19:06ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20600182060018Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjectsFabio Borgonovo0Carlo Alberto Stangalini1Carmine Tinelli2Chiara Mariani3Davide Mileto4Maria Vittoria Cossu5Laura Abbati6Lara Bilardo7Gloria Gagliardi8Miriam Cutrera9Martina Pellicciotta10Luciana Armiento11Gianfranco Dedivitiis12Amedeo F. Capetti13Giuliano Rizzardini14‘Luigi Sacco’ University Hospital’San Giuseppe Moscati’ FoundationFondazione IRCCS Policlinico‘Luigi Sacco’ University Hospital‘Luigi Sacco’ University Hospital‘Luigi Sacco’ University Hospital’San Giuseppe Moscati’ Foundation’San Giuseppe Moscati’ Foundation‘Luigi Sacco’ University Hospital‘Luigi Sacco’ University Hospital‘Luigi Sacco’ University Hospital‘Luigi Sacco’ University Hospital‘Luigi Sacco’ University Hospital‘Luigi Sacco’ University Hospital‘Luigi Sacco’ University HospitalVaccination toward SARS-CoV-2 reduced mortality and ‘boosters’ are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home “San Giuseppe Moscati” who had received two doses of the BNT162b2 vaccine were enrolled. The antibody response was assessed by the DiaSorin LIAISON-CLIA S1/S2® IgG solution. Cutoff levels for response (>39 BAU/mL) and neutralizing activity (>208 BAU/mL) were derived from DiaSorin official data. Serology was assessed before and after the first vaccination, and 2 weeks and 6 months after the second vaccination. Anti-S IgG in COVID-19 experienced, baseline IgG producers spiked after the first vaccination to median 5044 BAU/mL and decayed at 6 months to 2467.4 BAU/mL. Anti-S IgG in COVID-19 experienced, baseline IgG non-producers spiked after the second vaccination to median 1701.7 BAU/mL and decayed at 6 months to 904.8 BAU/mL. Anti-S IgG in COVID-19 naïve subjects spiked after the second vaccination to median 546 BAU/mL and decayed at 6 months to 319.8 BAU/mL. The differences between sequential timepoint levels in each group were statistically significant (p < .0001). Serology analysis revealed different kinetics between COVID-19 experienced subjects depending on baseline response, possibly predicting different IgG persistence in blood.http://dx.doi.org/10.1080/21645515.2022.2060018covid-19sars-cov-2spikeiggantibodykineticsdeclinevaccine |
| spellingShingle | Fabio Borgonovo Carlo Alberto Stangalini Carmine Tinelli Chiara Mariani Davide Mileto Maria Vittoria Cossu Laura Abbati Lara Bilardo Gloria Gagliardi Miriam Cutrera Martina Pellicciotta Luciana Armiento Gianfranco Dedivitiis Amedeo F. Capetti Giuliano Rizzardini Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects Human Vaccines & Immunotherapeutics covid-19 sars-cov-2 spike igg antibody kinetics decline vaccine |
| title | Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects |
| title_full | Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects |
| title_fullStr | Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects |
| title_full_unstemmed | Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects |
| title_short | Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects |
| title_sort | decay rate of antis1 s2 igg serum levels after 6 months of bnt162b2 vaccination in a cohort of covid 19 naive and covid 19 experienced subjects |
| topic | covid-19 sars-cov-2 spike igg antibody kinetics decline vaccine |
| url | http://dx.doi.org/10.1080/21645515.2022.2060018 |
| work_keys_str_mv | AT fabioborgonovo decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT carloalbertostangalini decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT carminetinelli decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT chiaramariani decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT davidemileto decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT mariavittoriacossu decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT lauraabbati decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT larabilardo decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT gloriagagliardi decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT miriamcutrera decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT martinapellicciotta decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT lucianaarmiento decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT gianfrancodedivitiis decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT amedeofcapetti decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects AT giulianorizzardini decayrateofantis1s2iggserumlevelsafter6monthsofbnt162b2vaccinationinacohortofcovid19naiveandcovid19experiencedsubjects |